Purple Biotech Ltd PPBT
1.53 USD -0.07 (-4.09%)
Regular-session close
1.50 -0.02 -1.63%
After hours · Nov 20, 4:21 PM ET
1.29 Day range 1.56
0.924 52-week range 8.74
- YTD
- -76.82%
- 1 year
- -79.99%
News
benzinga.com Purple Biotech Presents Preclinical Data On IM1240, Lead Capped Tri-Specific Antibody From CAPTN-3 Platform, In Plenary Oral Session At 38th EORTC-NCI-AACR Symposium Plenary oral presentation by Mount Sinai immunologist Dr. Amir Horowitz highlights Purple Biotech's CAPTN-3 platform of capped tri-specific antibodies, designed to engage T cells and NK cells against…
globenewswire.com Purple Biotech's IM1240, a CAPTN-3-Capped Tri-Specific T- and NK-Cell Engager Targeting 5T4, Shows Robust Tumor Killing in Immunotherapy-Resistant Cancer Models in Plenary Oral Presentation at EORTC-NCI-AACR Symposium REHOVOT, Israel, Nov. 20, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a biotechnology company developing a next-generation immunotherapy…benzinga.com Purple Biotech Q3 EPS $(0.60) Beats $(2.88) Estimate Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(2.88) by 79.17 percent. This is a 79.02 percent increase over losses of…
globenewswire.com Purple Biotech Reports Third Quarter 2026 Financial Results and Provides Business Update IM1240 tri-specific antibody (capped-CD3x5T4xNKG2A): Investigational New Drug (IND) application submission planned during 2027, followed by a first-in-human studybenzinga.com Purple Biotech’s Abstract On IM1240, Lead Tri-Specific Antibody From CAPTN-3 Platform, Accepted For Oral Presentation At 38th EORTC-NCI-AACR Symposium Oral presentation: November 20, 2026 at 15:00 CETREHOVOT, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a biotechnology company
